Guardant Health Operating Income 2017-2022 | GH

Guardant Health operating income from 2017 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Guardant Health Annual Operating Income
(Millions of US $)
2021 $-411
2020 $-255
2019 $-82
2018 $-93
2017 $-77
2016 $-44
Guardant Health Quarterly Operating Income
(Millions of US $)
2022-03-31 $-123
2021-12-31 $-98
2021-09-30 $-107
2021-06-30 $-98
2021-03-31 $-108
2020-12-31 $-91
2020-09-30 $-74
2020-06-30 $-55
2020-03-31 $-35
2019-12-31 $-26
2019-09-30 $-17
2019-06-30 $-15
2019-03-31 $-24
2018-12-31 $-27
2018-09-30 $-24
2018-06-30 $-23
2018-03-31 $-19
2017-12-31
2017-09-30 $-29
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.748B $0.374B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00